Corvus Pharmaceuticals, founded in 2014, is a clinical-stage biopharmaceutical company with a mission to bring cleverly-designed medicine to patients with the most difficult-to-treat cancers, immune disorders, and infectious diseases. They have rapidly developed a deep pipeline of potentially breakthrough investigational medicines that are potent, selective, and convenient to administer. Their focus is on developing ITK inhibition as a new approach to immunotherapy, targeting the modulation of T cells.

This significant opportunity parallels the success of their inventors and scientists who developed anti-cancer and auto-immune disease medicines such as Rituxan, Imbruvica, and Zelboraf. Corvus Pharmaceuticals has a seasoned team of biopharma industry leaders who are dedicated to developing new medicines for patients in need. They believe in putting patients first and promptly report their preclinical and clinical data at major scientific meetings, contributing to the advancement of medicine for the benefit of patients.

Join Corvus Pharmaceuticals and contribute your talent and expertise to improve the lives of people with cancer, immune disorders, and infectious diseases